Inimmune announced that it raised $22 million in Series A funding, led by Two Bear Capital. The company plans to use the Series A investment to advance at least two late-stage pre-clinical drug candidates in oncology and allergy through Phase I human clinical trials. This was Inimmune’s first outside investment. More than $12 million in research grants and contracts have been procured since 2016, including a recent $2 million grant from the National Institutes of Health.
Inimmune’s focus is to discover and develop novel innate immune modulating compounds for treatment of a host of immune diseases. Currently, the company’s pipeline is focused on utilizing several late-stage Toll-like receptor (TLR) agonists in immuno-oncology, food allergy, and allergic rhinitis. Next generation projects are focused on developing these agents as adjuvants for use with novel phage-based vaccines to prevent Gram-negative bacterial infections and for use with an opioid vaccine to prevent drug overdose.
“Effectively harnessing the incredible power of the human immune system has the potential to prevent or cure the most devastating diseases faced by humanity – from Covid-19, to cancer, to neurodegenerative diseases and more – and the need for solutions today is more urgent than ever,” said Two Bear Capital’s Michael Goguen. “The team at Inimmune combines world-class immunology and vaccine expertise, proven track records and a passion for solving some of the most important medical crises of our time. We are honored to be partners with them as they advance their promising therapies to the next level.”